Iovance Biotherapeutics (IOVA) is a commercial-stage pharmaceutical company primarily focused on developing and marketing novel T cell-based cancer immunotherapies. Currently, Iovance has two cancer drugs in its portfolio — Amtagvi and Proleukin. While Proleukin is approved to treat two cancer indications, namely metastatic renal cell carcinoma (mRCC) and metastatic melanoma, Amtagvi is approved for advanced melanoma indication. The company is developing its pipeline candidates, consisting of tumor-infiltra ...